Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-25-008031
Filing Date
2025-05-20
Accepted
2025-05-20 16:56:06
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q rsls-20250331x10q.htm   iXBRL 10-Q 1218003
2 EX-31.1 rsls-20250331xex31d1.htm EX-31.1 11628
3 EX-31.2 rsls-20250331xex31d2.htm EX-31.2 12002
4 EX-32.1 rsls-20250331xex32d1.htm EX-32.1 9297
5 EX-32.2 rsls-20250331xex32d2.htm EX-32.2 9221
  Complete submission text file 0001558370-25-008031.txt   5618156

Data Files

Seq Description Document Type Size
6 EX-101.SCH rsls-20250331.xsd EX-101.SCH 37117
7 EX-101.CAL rsls-20250331_cal.xml EX-101.CAL 51031
8 EX-101.DEF rsls-20250331_def.xml EX-101.DEF 202357
9 EX-101.LAB rsls-20250331_lab.xml EX-101.LAB 343258
10 EX-101.PRE rsls-20250331_pre.xml EX-101.PRE 300761
68 EXTRACTED XBRL INSTANCE DOCUMENT rsls-20250331x10q_htm.xml XML 823964
Mailing Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673
Business Address 1001 CALLE AMANECER SAN CLEMENTE CA 92673 949-429-6680
ReShape Lifesciences Inc. (Filer) CIK: 0001427570 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37897 | Film No.: 25969658
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)